Quest Diagnostics stock heads into October 22 results with Q2 growth now in view

Published on 10/04/2026 at 21:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock heads toward October 22 results after Q2 revenue rose 10.2 percent to USD 3.04 billion. Analysts cite a USD 237.08 target.

Börsen-Trading-Floor mit Händlern und Gesundheitssektor-Kurscharts auf Bildschirmen — Quest Diagnostics US74834L1008 wird redaktionell mit Börsen-Trading-Floor und Gesundheitssektor-Charts auf großen Bildschirmen inszeniert, Illustration mit AI erstellt.

Quest Diagnostics stock is heading toward its October 22, 2026, earnings release after the company delivered USD 3.04 billion in second-quarter revenue and adjusted EPS of USD 3.12. Quest Diagnostics announced on September 22, 2026, that it will publish third-quarter results before the market opens on October 22, 2026.

Q2 revenue sets the baseline

The second-quarter revenue figure was 10.2 percent higher than a year earlier, according to MarketBeat. Adjusted EPS of USD 3.12 exceeded the USD 2.82 consensus estimate by USD 0.30, while the prior-year figure was USD 2.62.

The Q2 performance gives the October release a clear benchmark: revenue of USD 3.04 billion, adjusted EPS of USD 3.12 and full-year adjusted EPS guidance of USD 11.05 to USD 11.25. The guidance range was also cited by Fortune in its Q2 2026 earnings-call transcript.

Analyst target sits near the stock

Analyst expectations remain constructive but measured. MarketBeat lists a Moderate Buy consensus from 13 analysts, including one Strong Buy, five Buy ratings and seven Hold ratings, with an average price target of USD 237.08.

That target is USD 3.76 above the October 2 close, equal to 1.61 percent above the price. The limited gap places greater weight on the October report's revenue progression, EPS delivery and any change to the full-year guidance.

Stock closes at USD 233.32

Quest Diagnostics closed at USD 233.32 on the NYSE on October 2, 2026, up 0.96 percent for the session. The price stood below the 52-week high of USD 248.84 and above the 52-week low of USD 171.18, while market capitalization was USD 25.7 billion.